Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer

The therapeutic effectiveness of oncolytic viruses (OVs) delivered intravenously is limited by the development of neutralizing antibody responses against the virus. To circumvent this limitation and to enable repeated systemic administration of OVs, here we develop Synthetic RNA viruses consisting o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kennedy, Edward M., Denslow, Agnieszka, Hewett, Jacqueline, Kong, Lingxin, De Almeida, Ana, Bryant, Jeffrey D., Lee, Jennifer S., Jacques, Judy, Feau, Sonia, Hayes, Melissa, McMichael, Elizabeth L., Wambua, Daniel, Farkaly, Terry, Rahmeh, Amal A, Herschelman, Lauren, Douglas, Danielle, Spinale, Jacob, Adhikari, Sanmit, Deterling, Jessica, Scott, Matt, Haines, Brian B., Finer, Mitchell H., Ashburn, Ted T, Quéva, Christophe, Lerner, Lorena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546900/
https://www.ncbi.nlm.nih.gov/pubmed/36207308
http://dx.doi.org/10.1038/s41467-022-33599-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9546900/
https://www.ncbi.nlm.nih.gov/pubmed/36207308
http://dx.doi.org/10.1038/s41467-022-33599-w

Ejemplares similares